Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases

2014 ◽  
Vol 3 (4) ◽  
pp. 449-466 ◽  
Author(s):  
Christel J Menet
Keyword(s):  
Inflammatory Diseases ◽  
Therapeutic Agents

Monoclonal Antibodies as Therapeutic Agents for Inflammatory Diseases

2021 ◽  
pp. 1-54
Author(s):  
Jéssica Bairos ◽  
Emanuel V. Capela ◽  
Ana P.M. Tavares ◽  
Mara G. Freire
Keyword(s):  
Monoclonal Antibodies ◽  
Inflammatory Diseases ◽  
Therapeutic Agents

scholarly journals The Development of Toad Toxins as Potential Therapeutic Agents

Toxins ◽  
2018 ◽  
Vol 10 (8) ◽  
pp. 336 ◽  
Author(s):  
Ji Qi ◽  
Abu Zulfiker ◽  
Chun Li ◽  
David Good ◽  
Ming Wei
Keyword(s):  
Molecular Basis ◽  
Molecular Mechanisms ◽  
Therapeutic Potential ◽  
Inflammatory Diseases ◽  
Indole Alkaloids ◽  
Therapeutic Agents ◽  
Chemical Components ◽  
Individual Compound ◽  
Comprehensive Understanding ◽  
The Individual

Toxins from toads have long been known to contain rich chemicals with great pharmaceutical potential. Recent studies have shown more than 100 such chemical components, including peptides, steroids, indole alkaloids, bufogargarizanines, organic acids, and others, in the parotoid and skins gland secretions from different species of toads. In traditional Chinese medicine (TCM), processed toad toxins have been used for treating various diseases for hundreds of years. Modern studies, including both experimental and clinical trials, have also revealed the molecular mechanisms that support the development of these components into medicines for the treatment of inflammatory diseases and cancers. More recently, there have been studies that demonstrated the therapeutic potential of toxins from other species of toads, such as Australian cane toads. Previous reviews mostly focused on the pharmaceutical effects of the whole extracts from parotoid glands or skins of toads. However, to fully understand the molecular basis of toad toxins in their use for therapy, a comprehensive understanding of the individual compound contained in toad toxins is necessary; thus, this paper seeks to review the recent studies of some typical compounds frequently identified in toad secretions.

Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseases

2021 ◽  
Author(s):  
Chi Teng Vong ◽  
Hisa Hui Ling Tseng ◽  
Peifen Yao ◽  
Hua Yu ◽  
Shengpeng Wang ◽  
...  
Keyword(s):  
Nlrp3 Inflammasome ◽  
Inflammatory Diseases ◽  
Therapeutic Agents ◽  
Inflammasome Inhibitors

scholarly journals Potential Effects of Melatonin and Micronutrients on Mitochondrial Dysfunction during a Cytokine Storm Typical of Oxidative/Inflammatory Diseases

Diseases ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 30
Author(s):  
Virna Margarita Martín Giménez ◽  
Natalia de las Heras ◽  
León Ferder ◽  
Vicente Lahera ◽  
Russel J. Reiter ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Mitochondrial Dysfunction ◽  
Metabolic Disorders ◽  
Inflammatory Diseases ◽  
Therapeutic Agents ◽  
Cytokine Storm ◽  
Natural Substances ◽  
Inflammatory Status ◽  
Close Relationship

Exaggerated oxidative stress and hyper-inflammation are essential features of oxidative/inflammatory diseases. Simultaneously, both processes may be the cause or consequence of mitochondrial dysfunction, thus establishing a vicious cycle among these three factors. However, several natural substances, including melatonin and micronutrients, may prevent or attenuate mitochondrial damage and may preserve an optimal state of health by managing the general oxidative and inflammatory status. This review aims to describe the crucial role of mitochondria in the development and progression of multiple diseases as well as the close relationship among mitochondrial dysfunction, oxidative stress, and cytokine storm. Likewise, it attempts to summarize the main findings related to the powerful effects of melatonin and some micronutrients (vitamins and minerals), which may be useful (alone or in combination) as therapeutic agents in the treatment of several examples of oxidative/inflammatory pathologies, including sepsis, as well as cardiovascular, renal, neurodegenerative, and metabolic disorders.

scholarly journals A Review of Botanical Characteristics, Traditional Usage, Chemical Components, Pharmacological Activities, and Safety ofPereskia bleo(Kunth) DC

2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Sogand Zareisedehizadeh ◽  
Chay-Hoon Tan ◽  
Hwee-Ling Koh
Keyword(s):  
Inflammatory Diseases ◽  
Therapeutic Agents ◽  
Chemical Components ◽  
Pharmacological Properties ◽  
Pharmacological Activities ◽  
Lead Compounds ◽  
National University ◽  
Botanical Characteristics ◽  
Prevention Of Cancer ◽  
Insect Repellant

Pereskia bleo, a leafy cactus, is a medicinal plant native to West and South America and distributed in tropical and subtropical areas. It is traditionally used as a dietary vegetable, barrier hedge, water purifier, and insect repellant and for maintaining health, detoxification, prevention of cancer, and/or treatment of cancer, hypertension, diabetes, stomach ache, muscle pain, and inflammatory diseases such as dermatitis and rheumatism. The aim of this paper was to provide an up-to-date and comprehensive review of the botanical characteristics, traditional usage, phytochemistry, pharmacological activities, and safety ofP. bleo. A literature search using MEDLINE (via PubMed), Science direct, Scopus and Google scholar and China Academic Journals Full-Text Database (CNKI) and available eBooks and books in the National University of Singapore libraries in English and Chinese was conducted. The following keywords were used:Pereskia bleo, Pereskia panamensis, Pereskia corrugata, Rhodocacus corrugatus, Rhodocacus bleo, Cactus panamensis, Cactus bleo, Spinach cactus, wax rose, Perescia, and Chinese rose. This review revealed the association between the traditional usage ofP. bleoand reported pharmacological properties in the literature. Further investigation on the pharmacological properties and phytoconstituents ofP. bleois warranted to further exploit its potentials as a source of novel therapeutic agents or lead compounds.

scholarly journals Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades

2021 ◽  
Vol 14 (8) ◽  
pp. 710
Author(s):  
Mohd. Imran ◽  
Syed Mohammed Basheeruddin Asdaq ◽  
Shah Alam Khan ◽  
Dhanalekshmi Unnikrishnan Meenakshi ◽  
Abdulhakeem S. Alamri ◽  
...  
Keyword(s):  
Protein Kinase ◽  
Kinase Inhibitors ◽  
Inflammatory Diseases ◽  
The United States ◽  
Therapeutic Agents ◽  
Protein Kinase Inhibitors ◽  
Patent Expiry ◽  
United States Food ◽  
The Usa ◽  
States Food

Protein kinase inhibitors (PKIs) are important therapeutic agents. As of 31 May 2021, the United States Food and Drug Administration (USFDA) has approved 70 PKIs. Most of the PKIs are employed to treat cancer and inflammatory diseases. Imatinib was the first PKI approved by USFDA in 2001. This review summarizes the compound patents and the essential polymorph patents of the PKIs approved by the USFDA from 2001 to 31 May 2021. The dates on the generic drug availability of the PKIs in the USA market have also been forecasted. It is expected that 19 and 48 PKIs will be genericized by 2025 and 2030, respectively, due to their compound patent expiry. This may reduce the financial toxicity associated with the existing PKIs. There are nearly 535 reported PKs. However, the USFDA approved PKIs target only about 10–15% of the total said PKs. As a result, there are still a large number of unexplored PKs. As the field advances during the next 20 years, one can anticipate that PKIs with many scaffolds, chemotypes, and pharmacophores will be developed.

Development of Proteinase-Activated Receptor 1 Antagonists as Therapeutic Agents for Thrombosis, Restenosis and Inflammatory Diseases

2003 ◽  
Vol 9 (28) ◽  
pp. 2349-2365 ◽  
Author(s):  
Ho-Sam Ahn ◽  
Samuel Chackalamannil ◽  
George Boykow ◽  
Michael Graziano ◽  
Carolyn Foster
Keyword(s):  
Inflammatory Diseases ◽  
Therapeutic Agents
Sign in / Sign up

Export Citation Format

Share Document